Research Paper Volume 15, Issue 10 pp 4444—4464
Development and validation of a novel T cell proliferation-related prognostic model for predicting survival and immunotherapy benefits in melanoma
Figure 8. Immune checkpoint genes expression, IPSs and immunotherapy benefits of patients in the two risk groups. (A) The differences in immune checkpoint gene expression between the high-risk and low-risk groups. (B–E) CR/PR patients had significantly lower risk scores than SD/PD patients in the iMvigor210 (F), PRJEB25780 (G), PRJNB23709 (H), and GSE35640 (I) cohorts.